Axatilimab Demonstrates Effectiveness in Refractory/Recurrent GVHD.

Published Date: 15 Dec 2023

lowest dose produced the least amount of toxicity and the highest overall response rate.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Expert Q&A: A Drug Holiday for Metastatic Prostate Cancer?

2.

Precision Medicine in mHSPC: Integrating Novel Biomarkers, Imaging, and Emerging Targeted Agents

3.

For elderly, unfit patients, the all-oral AML regimen shows promise.

4.

Can Prior Authorization Be Better With Artificial Intelligence?

5.

Benefits of perioperative radiotherapy for liver cancer with a high risk of recurrence are investigated in research.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot